Clinical trials: HIV-infection/AIDS
HIV Infections
A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers
The purpose of this study is to evaluate the safety and tolerability of plasmid DNA and recombinant MVA (Modified Vaccinia Virus Ankara) in a prime-boost regimen.
- Trial name
- NCT01371175
- Testing
- DNA.HIVA, MVA.HIVA
- Where
- 2 sites in Kenya, United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV-1-infection, ART
Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving…
- Conditions
- HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection
- Trial name
- NCT05700630
- Testing
- FT538, Vorinostat
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
HIV Infection
Atripla to Raltegravir Switch Study for CNS Toxicity
The purpose of the study is to investigate the benefits of switching away from efavirenz (part of the combination pill, Atripla®) in patients with central nervous system side effects (such as insomnia {difficulty with sleeping}…
- Trial name
- SSAT036 (NCT01195467)
- Testing
- Truvada/Raltegravir
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- St Stephens Aids Trust
Organic, Including Symptomatic, Mental Disorders, Substance Use
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions).
- Conditions
- Organic, Including Symptomatic, Mental Disorders, Substance Use, Schizophrenia, Mood [Affective] Disorders
- Trial name
- COMO-GMC (NCT03847753)
- Testing
- Organic Disorders, Substance Use Disorders, Schizophrenia Disorders
- Volunteers
- 5,940,299 people
- Sponsor
- University of Aarhus
HIV Infections, Pregnancy
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
The best anti-HIV treatment regimen for pregnant women is not known. Protease inhibitors (PIs) are often used, but they have side effects that may be harmful for pregnant women.
- Trial name
- NCT00017719
- Testing
- Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate
- Where
- 49 sites in United States, Brazil and 2 more
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Treatment
First in Human Study of TLC-ART 101 (ACTU 2001)
This study is a prospective, open-label, single-site, first-in-human study of a long-acting, injectable combination antiretroviral therapy platform, with a pharmacologically-guided adaptive design for dose escalation…
- Conditions
- Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
- Trial name
- NCT05850728
- Testing
- TLC-ART
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
A Study of 1592U89 in HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
- Trial name
- NCT00002200
- Testing
- Abacavir sulfate
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infection, Pain
Targeting Effective Analgesia in Clinics for HIV - Patient Cohort
The TEACH patient cohort will characterize a clinic sample of HIV-infected patients on chronic opioid therapy (COT) by describing basic demographics and health status, including characteristics of pain (severity and…
- Conditions
- HIV Infection, Pain, Drug Dependence
- Trial name
- TEACH (NCT02525731)
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- Boston Medical Center
HIV Infections
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
The purpose of this study is to determine the safety of and immune response to two experimental vaccines, designed for use in combination, for the prevention of HIV infection in healthy adults.
- Trial name
- NCT00428337
- Testing
- EP-1233, MVA-mBN32
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)
The study evaluates if there is relationship between the kinds of bacteria living in the anus (also known as the anal microbiome) and the risk of human papillomavirus (HPV) infection or HPV-related pre-cancer (high-grade squamous…
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
- Trial name
- ULACNet-104 (NCT06651957)
- Testing
- Biospecimen Collection, Questionnaires
- Where
- 3 sites in United States, Mexico and 1 more
- Volunteers
- 217 people
- Sponsor
- University of California, San Francisco
HIV Infections
Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting.
- Trial name
- IDCaPP (NCT05867212)
- Testing
- Cabotegravir Injection [Apretude]
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kelley-Ross & Associates, Inc.
HIV Infections
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
Participants will receive an infusion of both study drugs (3BNC117-LS and 10-1074-LS) and will discontinue antiretroviral therapy (which is the treatment for HIV) two days later.
- Trial name
- NCT05079451
- Testing
- 3BNC117-LS, 10-1074-LS
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts <=…
- Trial name
- NCT00002095
- Testing
- Ganciclovir
- Where
- 19 sites in United States
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche
HIV Infection
Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial
This study will determine whether 36 months of daily atorvastatin or rosuvastatin have equivalent effects in reduction of immune activation, inflammation and immune aging, when given as adjunct therapy among patients receiving…
- Trial name
- STAR (NCT03037372)
- Testing
- ART, Atorvastatin, ART, Rosuvastatin, ART, No statin
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Makerere University
HIV-1-infection
A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV
This is a randomized open-label trial to examine the safety and immunogenicity of INO-6160 (synthetic DNAs encoding a native-like HIV Env Trimer and Interleukin-12), alone or in a prime-boost regimen with VRC HIV Env Trimer 4571…
- Trial name
- NCT05828095
- Testing
- INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Stroke
Impact of HIV-infection on Clinical Characteristics and Outcomes on Stroke in Uganda
The investigators will recruit participants from three tertiary care hospitals in Uganda into an observational cohort study of people living with HIV/AIDS (PLWHA) and HIV-uninfected persons matched for gender and residency…
- Trial name
- NCT03072212
- Testing
- Observational study
- Where
- Uganda
- Volunteers
- 200 people
- Sponsor
- Mbarara University of Science and Technology
HIV Infections, Hyperlipidemia
Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients
open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
- Trial name
- NCT00184951
- Testing
- Rosuvastatin
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Hepatitis C
Hepatitis C Treatment Study in Myanmar
Hepatitis C is an important health problem in Myanmar affecting around 3% of the population. New drugs have been developed which have transformed the treatment of this disease around the world with very high success rates.
- Trial name
- NCT03158857
- Testing
- Sofosbuvir 400 mg
- Where
- Burma
- Sponsor
- Myanmar Oxford Clinical Research Unit
HIV Infections
Nutritional Status Among naïve HIV Infected Patients and HIV Infected Patients Receiving Highly Active Antiretroviral Therapy
A prospective cross-sectional study evaluates nutritional status and its relationship to the related factors in Thai HIV-infected patients who attending in out patient clinic.
- Trial name
- TNT-HIV 001 (NCT01899157)
- Where
- Thailand
- Volunteers
- 580 people
- Sponsor
- Thai Red Cross AIDS Research Centre
Influenza
Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)
This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.
- Trial name
- NCT01146119
- Testing
- Multimeric-001, 500 mcg, Adjuvanted PBS, PBS and TIV 15%
- Where
- 2 sites in Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.